Multimorbidity is Common in Axial Spondyloarthropathy and is Associated with Worse Disease Outcomes: Results from the ASRI cohort

From the Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; Department of Clinical Medicine, Trinity College Dublin, College Green, Dublin 2, Ireland; Department of Rheumatology, St. Vincent’s University Hospital, Dublin, Ireland. ASRI is supported by an unrestricted grant from Pfizer Pharmaceuticals and AbbVie Pharmaceuticals. GF is a recipient of the Bresnihan-Molloy Scholarship from the Royal College of Physicians of Ireland, funded by AbbVie pharmaceuticals. The funders had no role in the design of the study, collection of the data, analysis and interpretation of the data or any part of manuscript preparation. Address correspondence to Gillian Fitzgerald, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland. Email: gifitzge@tcd.ie.

From the Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; Department of Clinical Medicine, Trinity College Dublin, College Green, Dublin 2, Ireland; Department of Rheumatology, St. Vincent’s University Hospital, Dublin, Ireland. ASRI is supported by an unrestricted grant from Pfizer Pharmaceuticals and AbbVie Pharmaceuticals. GF is a recipient of the Bresnihan-Molloy Scholarship from the Royal College of Physicians of Ireland, funded by AbbVie pharmaceuticals. The funders had no role in the design of the study, collection of the data, analysis and interpretation of the data or any part of manuscript preparation. Address correspondence to Gillian Fitzgerald, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland. Email: gifitzge@tcd.ie.

From the Department of Rheumatology, St. James’s Hospital, Dublin, Ireland; Department of Clinical Medicine, Trinity College Dublin, College Green, Dublin 2, Ireland; Department of Rheumatology, St. Vincent’s University Hospital, Dublin, Ireland. ASRI is supported by an unrestricted grant from Pfizer Pharmaceuticals and AbbVie Pharmaceuticals. GF is a recipient of the Bresnihan-Molloy Scholarship from the Royal College of Physicians of Ireland, funded by AbbVie pharmaceuticals. The funders had no role in the design of the study, collection of the data, analysis and interpretation of the data or any part of manuscript preparation. Address correspondence to Gillian Fitzgerald, Department of Rheumatology, St. James’s Hospital, Dublin, Ireland. Email: gifitzge@tcd.ie.